NCT05745311

Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Kunming Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its PK/PD characteristics in patients.

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	The KPCXM18 injection	Intravenous infusion
DRUG	Placebo	Intravenous infusion

Timeline

• Start date: 2023-03-01
• Primary completion: 2024-05-01
• Completion: 2024-07-30
• First posted: 2023-02-27
• Last updated: 2023-02-28